Testosterone Blood Test: Normal Ranges & Causes | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Testosterone blood test

Testosterone (total, free and bioavailable). Also called: Total testosterone, Free testosterone, Bioavailable testosterone, Serum testosterone

Biomarker guideLast updated: October 30, 2026

Testosterone is the main male sex hormone, made mostly by the testes under the control of LH from the pituitary; women make smaller amounts. Labs report total testosterone, and some also report free or bioavailable testosterone, the fractions not locked up by SHBG.

LOINC 2986-8HormonesSexual

At a glance

What it measuresTotal testosterone, and on some tests the free (unbound) or bioavailable (free plus albumin-bound) fractions.
SampleBlood (serum), ideally in the morning while fasting.
Typical adult range (total)Men: 264-916 ng/dL (Labcorp, harmonized) or 250-1100 ng/dL (Quest MS). Women: 2-45 ng/dL (Quest MS); 10.0-55.0 premenopausal (Labcorp MS).
Common reasons it reads lowAfternoon or after-meal testing, obesity, opioids, androgen or steroid use, and pituitary or testicular problems.
Peptides that move itRaised by Human Chorionic Gonadotropin (hCG), Kisspeptin-10 and pulsatile Gonadorelin. Lowered to castrate levels by Leuprolide, Triptorelin and Goserelin (after an initial flare) and by Degarelix.
Lab codeLOINC 2986-8 total; 105121-8 LC/MS/MS; 2991-8 free; 103227-5 free calculated; 2990-0 bioavailable

What is Testosterone?

Testosterone is the principal androgen in men. LH from the pituitary stimulates the testes to make it, mostly in the Leydig cells, and rising testosterone in turn suppresses LH.

Labcorp uses the test to evaluate androgen excess or deficiency: in men for hypogonadism, hypopituitarism and Klinefelter syndrome, and in women for hirsutism, absent periods, virilization and androgen-producing tumors.

Sources: [1] [2]

How it is made and regulated

Where it is made

Most testosterone in men comes from the Leydig cells of the testes, under the control of LH. LH secretion is held in check by a negative feedback loop from testosterone and its metabolites.

Sources: [1]

What controls it

Testosterone follows a daily rhythm, highest in the morning: in men, levels were 20-25% lower at 4 p.m. than at 8 a.m., a difference that shrank to about 10% by age 70. A glucose drink or a mixed meal lowers it within an hour.

Sources: [3] [4]

How it travels in the blood

Roughly 60% to 90% of total testosterone is tightly bound to sex hormone-binding globulin (SHBG) and is not available to tissues. Most of the rest is loosely bound to albumin, and only about 0.5% to 2% circulates free. Free plus albumin-bound testosterone is called bioavailable testosterone.

Sources: [5] [6]

How long it lasts

We found no reliable half-life figure for testosterone in the sources reviewed for this page. For testing, what matters is the daily rhythm and the fall after meals.

Sources: [3] [4]

What it does

In the testes, testosterone is concentrated by a protein from the Sertoli cells, giving the high local levels needed for sperm production. In older men, low testosterone was linked with three sexual symptoms (poor morning erection, low sexual desire and erectile dysfunction).

Sources: [2] [7]

Reference ranges

Testosterone has separate ranges by method (immunoassay or mass spectrometry), by fraction (total, free or bioavailable), and by sex and age. Compare a result only with the range for the same test. Free testosterone is reported in pg/mL.

Labcorp (test 004226)

Method: Total testosterone, electrochemiluminescence immunoassay (ECLIA). Labcorp test page (retrieved October 30, 2026).

GroupRange (ng/dL)
Men, 20 years and older264-916
Women, 18 to 30 years13-71
Women, 31 to 40 years8-60
Women, 41 to 60 years4-50
Women, 61 to 80 years3-67
Women, over 80 years2-45
Children and teens
GroupRange (ng/dL)
Boys, 13 to 15 years28-656
Boys, 16 to 19 years150-785
Girls, 13 to 17 years12-71

No HoSt claim for this immunoassay. The adult male range (264-916 ng/dL) is based on healthy nonobese men (BMI under 30) aged 19-39 and footnoted to Travison and colleagues' harmonized ranges (2017).

Quest Diagnostics (test 15983)

Method: Total testosterone, chromatography/mass spectrometry. Quest Diagnostics test page (retrieved October 30, 2026).

GroupRange (ng/dL)
Men, 18 years and older250-1100
Women, 18 years and older2-45
Children and teens
GroupRange (ng/dL)
Boys, 14-17 years1000 or below
Girls, 14-17 years40 or below
Boys, 12-13 years420 or below
Boys, 11 years260 or below
Children 1-5 years (boys / girls)5 or below / 8 or below

HoSt-certified per Labcorp/Quest documentation (Quest brochure). Quest bases the 250 ng/dL lower limit on the 2.5th percentile of healthy men up to age 90, and notes that the harmonized lower limit for healthy nonobese young men is 264 ng/dL.

Labcorp (test 070001)

Method: Total testosterone, liquid chromatography/tandem mass spectrometry (LC/MS-MS). Labcorp test page (retrieved October 30, 2026).

GroupRange (ng/dL)
Men, over 18 years264.0-916.0
Women, premenopausal10.0-55.0
Women, postmenopausal7.0-40.0
Children and teens
GroupRange (ng/dL)
Prepubertal children (boys 1-10, girls 1-9 years)Below 2.5 to 10.0
Boys, Tanner stage II18.0-150.0
Boys, Tanner stage III100.0-320.0
Boys, Tanner stage IV200.0-620.0
Boys, Tanner stage V350.0-970.0
Girls, Tanner stages II-V7.0-38.0

HoSt-certified per Labcorp/Quest documentation (Labcorp document L8816). Designed for the low levels found in women, children and men with hypogonadism.

Labcorp (test 140226)

Method: Free testosterone, calculated from total testosterone, SHBG and albumin. Labcorp test page (retrieved October 30, 2026).

GroupRange (pg/mL)
Men, 18 to 30 years47.7-173.9
Men, 31 to 40 years42.3-190.0
Men, 41 to 50 years30.3-183.2
Men, 51 to 60 years35.8-168.2
Men, 61 to 70 years34.7-150.3
Men, 71 to 80 years31.7-120.8
Men, 81 to 100 years20.7-97.4
Women, 18 to 30 years1.1-12.9
Women, 31 to 40 years0.7-7.9
Women, 41 to 50 years0.5-6.0
Women, 51 to 60 years0.4-6.7
Women, 61 to 70 years0.4-7.0
Women, 71 to 80 years0.3-5.7
Women, 81 to 100 years0.2-5.6

Free testosterone in pg/mL. Labcorp also lists ranges for children and teens on its page.

ARUP Laboratories (test 2003246)

Method: Free testosterone by equilibrium dialysis and mass spectrometry. ARUP Laboratories test page (retrieved October 30, 2026).

GroupRange (pg/mL)
Men, 18 years and older47-244

Free testosterone in pg/mL. ARUP has not established ranges for males under 18 or for women with this reference method, and directs low-level testing to a different test.

Labcorp (test 143255)

Method: Bioavailable (free and weakly bound) testosterone, ammonium sulfate precipitation. Labcorp test page (retrieved October 30, 2026).

GroupRange (ng/dL)
Men40.0-250.0
Women0.0-9.5

Labcorp also reports the percentage free and weakly bound: men 9.0% to 46.0%, women 3.0% to 18.0%.

ARUP Laboratories (test 0070102)

Method: Bioavailable testosterone, calculated from total testosterone (immunoassay) and its binding to SHBG and/or albumin. ARUP Laboratories test page (retrieved October 30, 2026).

GroupRange (ng/dL)
Men, 18 years and older131-682
Children and teens
GroupRange (ng/dL)
Boys, 14-15 years10-337
Boys, 16-17 years35-509
Boys, Tanner stage IV40-485
Boys, Tanner stage V124-596

Male ranges. ARUP offers a separate mass-spectrometry panel for women and children.

Mass-spectrometry total testosterone at Labcorp (070001) and Quest (15983) is HoSt-certified per Labcorp/Quest documentation. We could not check this against the CDC's own certified-participants list, which returned a 403 error to our requests. Labcorp's immunoassay (004226) makes no HoSt claim; its adult male range is footnoted to the harmonized ranges of Travison and colleagues (2017). Quest publishes no reference range for its free or bioavailable testosterone tests ("See Laboratory Report"), so ARUP's published ranges are shown instead.

Units: Total and bioavailable testosterone are reported in ng/dL; free testosterone in pg/mL. Some studies use nmol/L: 264 ng/dL is 9.2 nmol/L. [12]

Sources: [1] [2] [8] [5] [9] [6] [10] [11] [12] [13]

Is there an "optimal" range?

Where "low" starts, and how much of the fall with age is normal, are both disputed.

Harmonized normal range

264-916 ng/dL

Travison and colleagues, four US and European cohorts (2017)

After calibrating all four cohorts to the CDC reference method, the 2.5th to 97.5th percentiles in healthy nonobese men aged 19-39 were 264 and 916 ng/dL; much of the difference between cohorts came from assay differences.

Sources: [13]

A 300 ng/dL cut-off is also widely used

300 ng/dL

Studies of testing timing and meals

Several studies treat 300 ng/dL as the lower normal limit; in one, some men below it in the afternoon were normal at every morning visit.

Sources: [3] [4]

Low testosterone plus symptoms

Total below 11 nmol/L (3.2 ng/mL) and free below 220 pmol/L (64 pg/mL)

European Male Ageing Study (Wu and colleagues, 2010)

Late-onset hypogonadism was best defined by at least three sexual symptoms together with low total and free testosterone; only the sexual symptoms tracked testosterone.

Sources: [7]

Levels fall with age within each man

About -0.124 nmol/L per year (BLSA); 1.6% per year (MMAS)

Baltimore Longitudinal Study of Aging (2001) and Massachusetts Male Aging Study (2002)

Following the same men over time showed steady declines, steeper than cross-sectional comparisons; incident poor health may speed the fall.

Sources: [14] [15]

Levels have also fallen across generations

Massachusetts Male Aging Study (Travison and colleagues, 2007)

An age-independent, population-level decline in testosterone was larger than the usual age-related decline and was not explained by smoking or obesity.

Sources: [16]

What raises it

FactorHowHow much
Morning samplingPhysiologyTestosterone peaks in the morning; afternoon levels in men were 20-25% lower.20-25% higher at 8 a.m. than 4 p.m. (smaller with age) [3]
Short bouts of exerciseLifestyleExercise causes a transient rise, partly from higher SHBG and hemoconcentration.No published magnitude [17]
Clomiphene, anticonvulsants and barbituratesMedicationLabcorp lists these as raising testosterone; in women, estrogen can raise measured testosterone.No published magnitude [2]
hCG, kisspeptin and pulsatile GnRHPeptidehCG acts like LH on the Leydig cells; kisspeptin and pulsed gonadorelin act upstream. See the peptide table below.hCG 6000 IU: total testosterone 178% of basal by day 4 [18] [19]

What lowers it

FactorHowHow much
Eating or a glucose drink before the testNutritionTestosterone fell within 20 minutes and bottomed out at about 60 minutes after a glucose load or mixed meal.Nadir drop 100 ng/dL (glucose) and 123 ng/dL (mixed meal) [4]
ObesityConditionObesity is the single most significant risk factor for testosterone deficiency in men; it can reverse with substantial weight loss.No published magnitude [20]
OpioidsMedicationRegular opioid use suppresses testosterone in men regardless of opioid type.Mean difference -164.78 vs controls (meta-analysis of 17 studies; units not stated in the abstract) [21]
Androgens and anabolic steroidsMedicationLabcorp lists androgens and steroids among drugs that can decrease testosterone.No published magnitude [2]
GnRH agonists and antagonistsPeptideUsed in prostate cancer to drive testosterone to castrate levels. Agonists cause an initial flare first; see the peptide table below.Leuprolide: below 50 ng/dL within four weeks [22]

Peptides that affect Testosterone

How each peptide in our library has been shown to affect testosterone, strongest evidence first. GnRH agonists (leuprolide, triptorelin, goserelin, buserelin, nafarelin) are listed as "lowers", but each first causes a short rise (the flare) before suppression; the size column gives both. "No clear effect" means testosterone was measured and did not change; "Unclear" means the results conflict.

PeptideEffect on TestosteroneSize of effectEvidence
Adrenocorticotropic Hormone (ACTH)RaisesTotal testosterone in 10 infants (5-22 months) on 6 weeks of ACTH therapy for infantile spasms: 2.7-fold rise vs pre-therapy, back to baseline 3 days after stopping (adrenal source). Adult male rats: acute ACTH raised serum testosterone without changing LHPharmacological ACTH raised testosterone (mostly adrenal androgens) in infants; in rats an acute dose raised testicular testosterone. No adult human data. [23] [24]Human trials
GonadorelinRaisesTotal testosterone, 22 young men with hypogonadotropic hypogonadism, pulsatile gonadorelin for 6 months (sustained, pulsatile): 0.78 ± 0.42 to 10.86 ± 7.68 nmol/L (P = 0.002)Given in pulses, as the brain normally releases GnRH, gonadorelin restored testosterone in men whose pituitary signal was missing. Continuous dosing works the opposite way (see GnRH agonists). [25]Human trials
Human Chorionic Gonadotropin (hCG)RaisesSix normal men, single 6000 IU hCG IM (acute): by day 4 total testosterone 178% ± 13% of basal, free testosterone 221% ± 18%, non-SHBG-bound 255% ± 19%. Retrospective series, 20 men with symptoms of hypogonadism, hCG monotherapy (median 8 months, sustained): mean testosterone 362 to 519.8 ng/dL (+49.9%, p = 0.006)hCG acts like LH on the testes and raises total and free testosterone within days. [18] [19]Human trials
Kisspeptin-10RaisesTotal testosterone, healthy men (15 in total, 12 controls). Acute: 8-h subcutaneous infusions of 1.25-10.0 nmol/kg/h dose-dependently raised testosterone vs vehicle (P < .0001). Sustained: testosterone stayed elevated after 5 days of continuous infusion (180 nmol/h), and daily 8-h infusions (150 nmol/h) sustained testosterone secretion for 12 daysKisspeptin-10 raises LH and then testosterone in men, and the effect held for 12 days with daily infusions. [26]Human trials
LiraglutideRaisesTotal testosterone, 30 obese men with functional hypogonadism, liraglutide 3.0 mg daily vs testosterone gel for 16 weeks (sustained, open-label RCT): +2.6 ± 3.5 nmol/L with liraglutide (+5.9 ± 7.2 with testosterone gel), with LH and FSH risingIn obese men with low testosterone, liraglutide raised testosterone, probably through weight loss. [27]Human trials
SemaglutideRaisesTotal testosterone in men with obesity-related functional hypogonadism. Open-label RCT, 42 obese men with type 2 diabetes and TT < 12 nmol/L, semaglutide 1.0 mg/week for 24 weeks: +4.1 nmol/L (testosterone replacement +8.3 nmol/L). Systematic review: GLP-1-based drugs raised total testosterone by 2.5-5.2 nmol/L, largely through weight loss. One database study instead linked semaglutide with a higher risk of a testosterone-deficiency diagnosis (RR 1.9)Raised low testosterone in men with obesity, mostly through weight loss; evidence is mixed and comes from small trials. [28]Human trials
TirzepatideRaisesTotal testosterone, controlled pilot study of 83 men with obesity and metabolic hypogonadism: 28 on tirzepatide 2.5 mg weekly (5 mg from the second month) plus diet and walking went from 186.5 to 424.0 ng/dL (medians) at 2 months, vs 192.0 to 266.0 ng/dL with diet and walking alone; free and bioavailable testosterone calculated with the Vermeulen formulaTestosterone more than doubled in men with obesity-related low testosterone over 2 months; a small, non-randomized pilot. [29]Human trials
BuserelinLowersTotal plasma testosterone, men with metastatic prostate cancer, buserelin 0.4 mg intranasally 3 times daily (58 alone, 13 with cyproterone): an initial increase during the first 2 weeks (flare), then suppression to castration levels. In a phase II study the transient rise occurred in 37% of 63 evaluable men. A 9.45 mg implant kept testosterone below the castration limit (0.58 ng/ml = 2 nmol/l) for 224 days (range 139-309) in 21 menA GnRH agonist: testosterone rises for about 2 weeks first (flare), then falls to castrate levels for as long as treatment continues. No FDA label (not approved in the US). [30] [31] [32]Human trials
CetrorelixLowersNormal men. Single SC doses (30 men, 5 per group): 1.0 mg lowered testosterone to 7.5 vs 15.8 nmol/L with placebo at 8 h; 2.0 and 5.0 mg to 4.9 and 2.2 nmol/L at 12 h; back to normal by 24-48 h. Daily 10 mg for 8 days (16 men) consistently suppressed testosterone. The Cetrotide label (approved for women in IVF) reports no initial release of gonadotropins (no flare)A GnRH antagonist: testosterone falls within hours, with no initial surge of LH and FSH. Approved only for IVF in women; the male data are from research studies. [33] [34] [35]Human trials
NafarelinLowersTotal testosterone. Initial flare: the Synarel label says nafarelin first causes "a temporary increase of gonadal steroidogenesis", and twice-daily dosing decreases gonadal steroid secretion by about 4 weeks; in dogs testosterone rose after the early injections. Suppression: 9 men with benign prostatic hyperplasia on 400 micrograms/day s.c. for 6 months all reached castrate testosterone, back to normal 6 months after stopping. The label gives no ng/dL castrate thresholdA brief rise at the start, then suppression to castrate levels with continued dosing. The US label covers endometriosis and early puberty, not male use. [36] [37] [38]Human trials
DulaglutideNo clear effectRandomized placebo-controlled crossover trial in healthy men (24 of 26 completed), 4 weeks: total testosterone (Roche ECLIA immunoassay) difference 0.9 nmol/l (95% CI -1.5 to 3.3) vs placebo, not significantFour weeks of dulaglutide did not change testosterone in healthy men. [39]Human trials
ExenatideNo clear effectProspective cohort, 51 men with type 2 diabetes starting GLP-1 receptor agonist therapy, 6 months: no significant change in total testosterone overall; men starting below 320 ng/dL rose (238.5 to 272.2 ng/dL) while higher starters fellNo overall testosterone change; men starting low tended to rise. Uncontrolled cohort. [40]Human trials
GanirelixNo clear effectWomen with PCOS (PMOS) without obesity, single subtherapeutic dose 0.025 mg (n = 8) or 0.0625 mg (n = 10), 8 h sampling (acute): testosterone unchanged while androstenedione fell 25-30%Very low single doses in women did not change testosterone. No data in men or at the IVF dose. [41]Human trials
GlucagonNo clear effectTotal testosterone, 18 healthy young men (baseline 21.2 ± 1.2 nmol/L), 8-hour IV glucagon 2 pmol/kg/min vs vehicle, randomized crossover (acute): no differenceA metabolically active glucagon infusion did not change testosterone in healthy men. [42]Human trials
OxytocinNo clear effectRandomized trial, 61 adults with obesity, intranasal oxytocin 24 IU four times daily vs placebo for 8 weeks (sustained): fasting testosterone and other sex steroids did not differ between groups (p's ≥ 0.140); assay not stated in the abstractEight weeks of intranasal oxytocin did not change testosterone in a randomized trial. [43]Human trials
MK-677 (Ibutamoren)UnclearTotal testosterone. 24 obese men, 25 mg/day for 8 weeks: total testosterone reduced vs placebo (P < 0.05) but the total testosterone/SHBG ratio (a free-testosterone index) unchanged. 65 adults aged 60-81, 25 mg/day for 2 years (sustained): total testosterone in men did not changeOne 8-week trial found lower total testosterone with no change in the free index; a 2-year trial in older adults found no change. [44] [45]Human trials
DegarelixLowersMen with prostate cancer, 240 mg loading then 80 mg monthly SC: testosterone at or below 50 ng/dL in 52% at day 1, 96% at day 3 and 99% at day 7 (leuprolide 0%, 0% and 1%); maintained below castration level in 97.2% from day 28 to day 364A GnRH antagonist: in the head-to-head trial 96% of men were at castrate level by day 3, against 0% on leuprolide, and suppression held through a year. [46] [47]FDA label
GoserelinLowersTotal testosterone, men with prostate cancer, depot 3.6 mg every 28 days (sustained). Initial flare: LH and FSH rise first, "with subsequent increases in serum levels of testosterone"; in a trial testosterone increased over the first week after a single 3.6 mg injection. Suppression: testosterone falls "into the range normally seen in surgically castrated men approximately 2-4 weeks after initiation of therapy" and stayed suppressed in trials with more than 2 years of follow-up. The label gives no ng/dL castrate thresholdLike other GnRH agonists, goserelin first raises testosterone for about a week, then suppresses it to castrate levels within 2-4 weeks. [48] [49]FDA label
LeuprolideLowersTotal testosterone, men with prostate cancer, depot dosing (sustained). Initial flare: testosterone rises "to approximately 50% above baseline during the first weeks of treatment" (45 mg depot: mean 435 to 608 ng/dL in the first week). Suppression: then declines to castrate levels (< 50 ng/dL) within four weeks (45 mg depot: mean 16 ng/dL by Week 4; 22.5 mg depot: castrate within 30 days in 87 of 92 patients)Leuprolide first raises testosterone by about half for a week or two (the "flare"), then drives it below 50 ng/dL within four weeks and keeps it there. [22]FDA label
TriptorelinLowersTotal testosterone. Flare: after the first dose there is "a transient surge in circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and estradiol", peaking on Day 4 (3.75 mg), Days 2-3 (11.25 mg) or Day 3 (22.5 mg). Suppression: testosterone then "declined thereafter to castrate levels (< 50 ng/dL) within four weeks"; castrate by Day 29 in 167 of 171 (97.7%) men on 11.25 mg and 125 of 137 (91.2%) on 3.75 mgTestosterone rises for a few days after the first injection, then falls to castrate levels within about four weeks and stays there. [50]FDA label
FOXO4-DRIRaisesNaturally aged male mice (20-24 months), FOXO4-DRI every other day for three doses: serum testosterone (Elecsys immunoassay) higher than untreated aged mice 30 days later; values shown only in a figureRaised testosterone in old mice by clearing senescent Leydig cells. No human data. [51]Animal studies
GhrelinRaisesMale Sprague-Dawley rats with streptozotocin type 1 diabetes: ghrelin raised plasma testosterone 3.75-fold vs untreated diabetic rats (P < 0.05)Raised testosterone in diabetic rats. No data in healthy animals or people. [52]Animal studies
IrisinRaisesMale mice on a high-fat diet, recombinant irisin by s.c. infusion for 8 weeks (sustained): serum testosterone, lowered by the diet, largely improved; FSH and LH unchangedIn obese mice irisin restored testosterone that the diet had lowered. No human dosing data. [53]Animal studies
MOTS-cRaisesSerum total testosterone, 80 male Wistar-Albino rats (obese and non-obese), intracerebroventricular MOTS-c 10 or 100 µM for 14 days (sustained): testosterone, LH and FSH rose, more in non-obese rats (p < 0.05); no values in the abstractRaised testosterone in rats when infused into the brain for two weeks. No human data. [54]Animal studies
OsteocalcinRaisesMice: circulating testosterone measured 1, 4 and 8 h after osteocalcin injection (3 ng/g of body weight) vs vehicle (acute); loss- and gain-of-function models showed osteocalcin drives Leydig-cell testosterone production. No human dosing dataIn mice, the bone hormone osteocalcin stimulated testosterone production by the testes. Not tested as a treatment in people. [55]Animal studies
ThymulinRaisesBoars (pigs), single IV thymulin 4.4, 44.4 or 444.4 ng/kg BW (acute): circulating total testosterone generally higher 2 to 3 h later (P<.01), depending on the boar's LH level and the doseIn boars, a thymulin injection raised testosterone for a few hours, depending on LH and dose. No human data. [56]Animal studies
CalcitoninLowersMale rats, pharmacological IV salmon calcitonin 10 MRC U/kg (acute): plasma testosterone and LH fell; single IV doses of calcitonin peptides lowered basal and hCG-stimulated testosterone (RIA) from 60 to 180 or 360 minutesLowered testosterone in rats at pharmacological doses, through lower LH. No human data. [57] [58]Animal studies
DeslorelinLowersMale rhesus macaques (n = 4), two 4.7-mg implants: serum testosterone suppressed (below 0.6 ng/mL for at least 30 d) in all 4, by day 26 in 2 and by 2 months in the other 2 (sustained)Suppressed testosterone in monkeys with a slow-release implant. Not approved for human use; no human male testosterone data. [59]Animal studies
Neuropeptide YLowersPlasma testosterone, adult male rats, NPY 5 µg/kg injected into the testis 1 h before an hCG challenge (1.0 U/kg IV): blunted the testosterone response (P<0.01); acute, local injectionBlunted the testosterone response to hCG when injected into rat testes. Not a systemic dosing study; no human data. [60]Animal studies
HumaninUnclearRodent studies only. Rats (single dose, 12 h): humanin had no significant effect on serum or intratesticular testosterone with or without Leydig-cell depletion. Mice with cyclophosphamide-induced oligoasthenozoospermia: the analog HNG increased serum testosterone. Male rats on paroxetine (humanin 1 mg/kg/day s.c.): reversed the paroxetine-induced fall in testosteroneHumanin and its analog restored testosterone only in rodents whose testosterone had been lowered by a drug; it did not change normal levels. No human data. [61] [62] [63]Animal studies

What high or low results can mean

A high result

In women, a high result is investigated for hirsutism, virilization, absent periods or lack of ovulation, and for androgen-producing ovarian or adrenal tumors and congenital adrenal hyperplasia.

  • Androgen-producing ovarian or adrenal tumors (women)
  • Congenital adrenal hyperplasia
  • Clomiphene, anticonvulsants or barbiturates
  • Estrogen therapy in women
  • hCG or kisspeptin

Next step: For women, a mass-spectrometry test is more reliable at low levels. Discuss high results with a clinician, especially with new hair growth, acne or menstrual changes.

Sources: [1] [2] [11]

A low result

A low total testosterone in a man may mean hypogonadism, but a single low value is often normal on a repeat morning, fasting test. Obesity, opioids and illness are common causes.

  • Afternoon or after-meal sampling
  • Obesity
  • Opioid use
  • Androgen or steroid use
  • Pituitary or testicular disorders
  • GnRH-agonist or antagonist treatment

Next step: Repeat a morning fasting total testosterone with an accurate assay. If total is borderline or SHBG may be abnormal, a free testosterone by equilibrium dialysis or calculation helps.

Sources: [64] [3] [4]

How the test works

SampleLabcorp takes serum or lithium-heparin plasma (004226) or serum only (mass spectrometry and free tests). Quest asks for 1 mL of serum and for age and sex on the request.
FastingThe Endocrine Society recommends morning fasting total testosterone; a glucose drink or a meal lowered testosterone, by 100-123 ng/dL at the low point.
TimingTest in the morning: levels were 20-25% lower at 4 p.m. than 8 a.m., and some men with low afternoon results were normal at every morning visit. Labcorp asks people to stop high-dose biotin at least 72 hours before immunoassay tests.
Lab differencesMass spectrometry is more accurate at low levels (women, children, men with hypogonadism). Direct analog immunoassays for free testosterone (such as Labcorp 144980) are unreliable: they read only a fraction of the true free level and vary with SHBG, so calculated or dialysis-based free testosterone is preferred.
RetestingWithin-person biological variation for testosterone was about 10% in men sampled weekly for 10 weeks, so repeat a borderline result before acting.
Labcorp order code004226: Testosterone, Total (immunoassay)
Labcorp order code070001: Testosterone, Total, LC/MS-MS
Labcorp order code140226: Testosterone, Free, Profile I (calculated)
Labcorp order code143255: Testosterone, Free and Weakly Bound (bioavailable)
Quest Diagnostics order code15983: Testosterone, Total, MS
ARUP Laboratories order code2003246: Testosterone, Free, by Dialysis and Mass Spectrometry
ARUP Laboratories order code0070102: Testosterone, Bioavailable and Total, with SHBG
LOINC codes
  • 2986-8: Testosterone [Mass/volume] in Serum or Plasma
  • 105121-8: Testosterone [Mass/volume] in Serum or Plasma by LC/MS/MS (total testosterone by mass spectrometry)
  • 2991-8: Testosterone Free [Mass/volume] in Serum or Plasma (free testosterone)
  • 103227-5: Testosterone Free [Mass/volume] in Serum or Plasma by Calculation (calculated free testosterone)
  • 2990-0: Testosterone.free+weakly bound [Mass/volume] in Serum or Plasma (bioavailable testosterone)
LOINC 2986-8 on loinc.org

Sources: [64] [4] [3] [1] [65] [8] [66] [67] [68] [69]

History

Testosterone testing has moved from early radioimmunoassays to standardized mass spectrometry, after studies showed that different assays gave very different numbers.

  1. 1970A radioimmunoassay for plasma testosterone is published. [70]
  2. 1999Vermeulen and colleagues show calculated free testosterone is reliable, while direct analog free testosterone assays are not. [67]
  3. 2007The Massachusetts Male Aging Study reports a population-level decline in testosterone across generations, independent of age. [16]
  4. 2010A consensus statement calls for standardized testosterone assays, and the CDC describes its standardization program. [71] [72]
  5. 2017Harmonized reference ranges for men (264-916 ng/dL at ages 19-39) are published using CDC-calibrated data. [13]
  6. 2018The Endocrine Society publishes its guideline on testosterone therapy in men with hypogonadism. [64]

FAQ

What is a normal testosterone level for men?

The harmonized adult range is 264-916 ng/dL, which Labcorp uses. Quest's mass-spectrometry range is 250-1100 ng/dL. Use the range printed on your report, because methods differ.

Sources: [13] [1] [8]

What is a normal testosterone level for women?

Much lower: 2-45 ng/dL on Quest's mass-spectrometry test, and 10.0-55.0 ng/dL premenopausal and 7.0-40.0 postmenopausal on Labcorp's.

Sources: [8] [2]

When should I get my testosterone tested?

In the morning, fasting. Levels were 20-25% lower at 4 p.m. than 8 a.m., and a glucose drink or meal lowered testosterone within an hour.

Sources: [3] [4]

What is the difference between total, free and bioavailable testosterone?

Total is everything in the blood. About 60% to 90% is bound to SHBG; the rest is mostly bound to albumin, and only 0.5% to 2% is free. Bioavailable means free plus albumin-bound.

Sources: [5] [6]

Which free testosterone test is best?

Equilibrium dialysis or a calculation from total testosterone, SHBG and albumin. Direct analog immunoassays are unreliable and read only a fraction of the true free level.

Sources: [67] [68] [5]

What does HoSt-certified mean?

The CDC Hormone Standardization (HoSt) Program checks that a lab's testosterone results match a reference method. Labcorp's and Quest's mass-spectrometry total testosterone tests are HoSt-certified per their own documentation; we could not check CDC's list directly because it returned an access-denied error.

Sources: [11] [12] [72]

Does testosterone decline with age?

Yes, within each man: about 1.6% per year in the Massachusetts Male Aging Study. Separately, average levels have fallen across generations independent of age.

Sources: [15] [16]

What testosterone level counts as low with symptoms?

In the European Male Ageing Study, late-onset hypogonadism was defined by at least three sexual symptoms with total testosterone below 11 nmol/L (3.2 ng/mL) and free testosterone below 220 pmol/L (64 pg/mL).

Sources: [7]

Do opioids lower testosterone?

Yes, in men. A meta-analysis of 17 studies found significantly lower testosterone in men with regular opioid use, regardless of opioid type; levels in women were not affected.

Sources: [21]

Why does leuprolide raise testosterone at first?

GnRH agonists first stimulate the pituitary, so testosterone rises about 50% above baseline in the first weeks (the "flare") before falling below 50 ng/dL within four weeks. This can briefly worsen prostate cancer symptoms, so doctors may cover the first weeks.

Sources: [22] [73]

Do GnRH antagonists cause a flare?

They work differently. With Degarelix, 96% of men were at castrate level by day 3 against 0% on Leuprolide in the head-to-head trial; the Cetrorelix label reports no initial release of gonadotropins.

Sources: [33] [34] [35] [46] [47]

Which peptides raise testosterone?

Human Chorionic Gonadotropin (hCG) raises it by acting like LH (178% of basal by day 4 after one dose), Kisspeptin-10 raises it in a dose-dependent way, and pulsatile Gonadorelin restored it in men with hypogonadotropic hypogonadism.

Sources: [25] [18] [19] [26]

References

  1. Labcorp. Test 004226: Testosterone, Total (ECLIA). Use, special instructions, limitations, specimen requirements, reference range (adult male interval footnoted to Travison et al. 2017) and LOINC map. labcorp.com/tests/004226/testosterone-total
  2. Labcorp. Test 070001: Testosterone, Total, Women, Children, and Hypogonadal Males, LC/MS-MS. Use, limitations, specimen requirements and reference ranges. labcorp.com/tests/070001/testosterone-total-women-children-and-hypogonadal-males-lc-ms-ms
  3. Brambilla DJ, Matsumoto AM, Araujo AB, et al. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907-13. PMID 19088162
  4. Gagliano-Jucá T, Li Z, Pencina KM, et al. Oral glucose load and mixed meal feeding lowers testosterone levels in healthy eugonadal men. Endocrine. 2019;63(1):149-156. PMID 30191441
  5. Labcorp. Test 140226: Testosterone, Free, Profile I (calculated free testosterone with total testosterone, SHBG and albumin). Use and reference ranges. labcorp.com/tests/140226/testosterone-free-profile-i
  6. Labcorp. Test 143255: Testosterone, Free and Weakly Bound (bioavailable). Use, method (ammonium sulfate precipitation) and reference range. labcorp.com/tests/143255/testosterone-free-and-weakly-bound
  7. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-35. PMID 20554979
  8. Quest Diagnostics. Test code 15983: Testosterone, Total, MS. Test directory entry (East region): methodology, specimen, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/15983/testosterone-total-ms?cc=PHP
  9. ARUP Laboratories. Test 2003246: Testosterone, Free, by Dialysis and Mass Spectrometry (Adult Males or Individuals on Testosterone Hormone Therapy). Reference interval and interpretive data. ltd.aruplab.com/Tests/Pub/2003246
  10. ARUP Laboratories. Test 0070102: Testosterone, Bioavailable and Total, Includes Sex Hormone-Binding Globulin (Adult Males or Individuals on Testosterone Hormone Therapy). Reference intervals. ltd.aruplab.com/Tests/Pub/0070102
  11. Labcorp. Testosterone by Mass Spectrometry (document L8816): states that Labcorp's total testosterone by LC/MS-MS (test 070001) is certified by the CDC Hormone Standardization (HoSt) Program. labcorp.com/tests/related-documents/L8816
  12. Quest Diagnostics. Male reproductive endocrinology one-pager (1173A): states that Quest's Total Testosterone LC-MS/MS assay is certified by the CDC HoSt Program, citing the CDC certified-participant list accessed April 4, 2024. questdiagnostics.com/content/dam/corporate/documents/resource/1173A_Quest-Endo_Male-Repro-1-Pager_v5.pdf
  13. Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161-1173. PMID 28324103
  14. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724-31. PMID 11158037
  15. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589-98. PMID 11836290
  16. Travison TG, Araujo AB, O'Donnell AB, et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196-202. PMID 17062768
  17. Zmuda JM, Thompson PD, Winters SJ. Exercise increases serum testosterone and sex hormone-binding globulin levels in older men. Metabolism. 1996;45(8):935-9. PMID 8769347
  18. Cooke RR, McIntosh RP, McIntosh JG, et al. Serum forms of testosterone in men after an hCG stimulation: relative increase in non-protein bound forms. Clin Endocrinol (Oxf). 1990;32(2):165-75. PMID 2347086
  19. Madhusoodanan V, Patel P, Lima TFN, et al. Human Chorionic Gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone > 300 ng/dL. Int Braz J Urol. 2019;45(5):1008-1012. PMID 31408289
  20. Fernandez CJ, Chacko EC, Pappachan JM. Male Obesity-related Secondary Hypogonadism - Pathophysiology, Clinical Implications and Management. Eur Endocrinol. 2019;15(2):83-90. PMID 31616498
  21. Bawor M, Bami H, Dennis BB, et al. Testosterone suppression in opioid users: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;149:1-9. PMID 25702934
  22. LUPRON DEPOT (leuprolide acetate for depot suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
  23. Voutilainen R, Riikonen R, Simell O, et al. The effect of ACTH therapy on serum dehydroepiandrosterone, androstenedione, testosterone and 5 alpha-dihydrotestosterone in infants. J Steroid Biochem. 1987;28(2):193-6. PMID 3041110
  24. Armario A, Perelló A, Lopez-Calderón A. Adrenocorticotropin administration increases testosterone secretion in adult male rats. Life Sci. 1986;39(13):1119-22. PMID 3018412
  25. Li CX, Tang ST, Zhang Q. Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism. Int J Endocrinol. 2015;2015:324524. PMID 26417369
  26. Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026;195(2):206-216. PMID 42549827
  27. Jensterle M, Podbregar A, Goricar K, et al. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8(3):195-202. PMID 30707677
  28. La Vignera S, Condorelli R. Effects of Incretin-Based Therapies on Testosterone Levels and Incretin Response in Men with Hypogonadism: A Systematic Literature Review Following PRISMA 2020 Guidelines. Pharmaceuticals (Basel). 2026;19(8). PMID 42653816
  29. La Vignera S, Cannarella R, Garofalo V, et al. Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study. Reprod Biol Endocrinol. 2025;23(1):92. PMID 40604795
  30. Schroeder FH, Lock TM, Chadha DR, et al. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol. 1987;137(5):912-8. PMID 2952810
  31. Veronesi A, Lo Re G, Dal Bo V, et al. Buserelin treatment of advanced prostatic cancer: a phase II study. Med Oncol Tumor Pharmacother. 1989;6(4):255-7. PMID 2515400
  32. Pettersson B, Varenhorst E, Petas A, et al. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Eur Urol. 2006;50(3):483-9. PMID 16626856
  33. Behre HM, Klein B, Steinmeyer E, et al. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab. 1992;75(2):393-8. PMID 1639941
  34. Behre HM, Böckers A, Schlingheider A, et al. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin Endocrinol (Oxf). 1994;40(2):241-8. PMID 8137524
  35. CETROTIDE (cetrorelix acetate for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
  36. SYNAREL (nafarelin acetate) nasal spray, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6
  37. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317(10):599-604. PMID 2441256
  38. Vickery BH, McRae GI, Briones WV, et al. Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist. J Androl. 1985;6(1):53-60. PMID 3156111
  39. Lengsfeld S, Probst L, Emara Y, et al. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. EBioMedicine. 2024;107:105284. PMID 39232425
  40. Graybill S, Hatfield J, Kravchenko M, et al. Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort. Andrology. 2021;9(3):792-800. PMID 33400403
  41. Cotellessa L, Maitre H, Giton F, et al. GnRH-receptor antagonism as a targeted approach to reproductive dysfunction in polycystic ovary syndrome. EBioMedicine. 2026;130:106398. PMID 42468113
  42. Izzi-Engbeaya C, Jones S, Crustna Y, et al. Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men. J Clin Endocrinol Metab. 2020;105(6):1899-905. PMID 32232363
  43. Galbiati F, Hiranandani S, Wronski ML, et al. Reproductive hormone stability with prolonged intranasal oxytocin in adults with obesity. Int J Obes (Lond). 2026;50(7):1508-1514. PMID 41951782
  44. Svensson J, Carlsson B, Carlsson LM, et al. Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Clin Endocrinol (Oxf). 1999;50(4):451-6. PMID 10468903
  45. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PMID 18981485
  46. FIRMAGON (degarelix) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b
  47. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-8. PMID 19035858
  48. ZOLADEX (goserelin implant), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
  49. Tanaka N, Fujimoto K, Hirao Y, et al. Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer. Arch Androl. 2007;53(2):87-90. PMID 17453688
  50. TRELSTAR (triptorelin pamoate for injectable suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
  51. Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284. PMID 31959736
  52. Lu CC, Chang CH, Chou JC, et al. Regulatory mechanism of ghrelin on testosterone secretion in type 1 diabetic rats. Reprod Fertil. 2025;6(3). PMID 40601674
  53. Mu Y, Dai HG, Luo LB, et al. Irisin alleviates obesity-related spermatogenesis dysfunction via the regulation of the AMPKα signalling pathway. Reprod Biol Endocrinol. 2021;19(1):135. PMID 34496874
  54. Ozturk Öztürk DA, Erden Y, Tekin S. Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats. Neurosci Lett. 2024;826:137722. PMID 38462167
  55. Oury F, Sumara G, Sumara O, et al. Endocrine regulation of male fertility by the skeleton. Cell. 2011;144(5):796-809. PMID 21333348
  56. Wise T, Ford JJ. Effects of the thymic peptide thymulin on in vitro and in vivo testicular steroid concentrations in white composite and Meishan boars. J Anim Sci. 1999;77(8):2240-51. PMID 10462005
  57. Mahrous TS, Nakhla AM. Pharmacological doses of calcitonin reduce sex hormone levels in rat plasma. Acta Endocrinol (Copenh). 1988;119(4):525-8. PMID 3144108
  58. Wang PS, Tsai SC, Hwang GS, et al. Calcitonin inhibits testosterone and luteinizing hormone secretion through a mechanism involving an increase in cAMP production in rats. J Bone Miner Res. 1994;9(10):1583-90. PMID 7817804
  59. Tran HD, Carroll KE, Mackiewicz AL, et al. Effects of Deslorelin on Testosterone Secretion and Testicular Volume in Male Rhesus Macaques (Macaca mulatta). J Am Assoc Lab Anim Sci. 2023;62(6):525-530. PMID 37844997
  60. Allen CD, Waser B, Körner M, et al. Neuropeptide Y acts within the rat testis to inhibit testosterone secretion. Neuropeptides. 2011;45(1):55-61. PMID 21112087
  61. Surampudi P, Chang I, Lue Y, et al. Humanin protects against chemotherapy-induced stage-specific male germ cell apoptosis in rats. Andrology. 2015;3(3):582-589. PMID 25891800
  62. Liu Y, Feng Q, Zou L, et al. Oligoasthenozoospermia is alleviated in a mouse model by [Gly14]-humanin-mediated attenuation of oxidative stress and ferroptosis. Andrology. 2025;13(6):1541-1555. PMID 39435863
  63. Köm Akipek RE, Çoban Ercan E, Akipek ME, et al. Humanin peptide ameliorates reproductive dysfunction and restores neuroendocrine mechanisms in SSRI-treated male rats. Reprod Biol. 2026;26(4):101254. PMID 42480246
  64. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID 29562364
  65. Labcorp. Test 144980: Testosterone, Free, Direct (direct analog enzyme immunoassay). Method and reference range. labcorp.com/tests/144980/testosterone-free-direct
  66. LOINC 2986-8: Testosterone [Mass/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/2986-8
  67. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-72. PMID 10523012
  68. Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab. 2001;86(6):2903. PMID 11397908
  69. Itkonen O, Jonker N, Aarsand AK, et al. The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men. Clin Chim Acta. 2024;555:117806. PMID 38341016
  70. Furuyama S, Mayes DM, Nugent CA. A radioimmunoassay for plasma testosterone. Steroids. 1970;16(4):415-28. PMID 5533947
  71. Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab. 2010;95(10):4542-8. PMID 20926540
  72. Vesper HW, Botelho JC. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol. 2010;121(3-5):513-9. PMID 20302935
  73. Pokuri VK, Nourkeyhani H, Betsy B, et al. Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms. J Natl Compr Canc Netw. 2015;13(7):e49-55. PMID 26150586

Educational information, not medical advice. Lab ranges and test codes were checked on October 30, 2026. Always use the range printed on your own report, and talk to a clinician about your results.